SCHEMBL31441577

SCHEMBL31441577

CC1(C)OB(c2cccnc2NC2CCC2)OC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ TRPM8 Q7Z2W7 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.36
▸ ADORA3 P0DMS8 2/20 0.34
▸ ADORA2A P29274 2/20 0.34
▸ ADORA1 P30542 2/20 0.34
▸ ADORA2B P29275 1/20 0.34
▸ GRM4 Q14833 2/20 0.34
▸ ROCK2 O75116 1/20 0.34
▸ CHRM4 P08173 1/20 0.34
▸ IRAK1 P51617 1/20 0.34
▸ IRAK4 Q9NWZ3 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ FLT3 P36888 2/20 0.33
▸ TYRO3 Q06418 2/20 0.33
▸ MERTK Q12866 2/20 0.33
▸ GAS6 Q14393 2/20 0.33
▸ AXL P30530 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26674783 0.94 PDE10A (0.37) LRRK2KDM4EGAAGRM4ROCK2
SCHEMBL16967950 0.78 LPL (0.35) KDM4E
SCHEMBL31441746 0.77 LRRK2 (0.33) LRRK2KDM4ETRPM8
SCHEMBL22574535 0.74 LPL (0.37) KDM4EHSD17B10
SCHEMBL31441693 0.74 USP30 (0.50) —
SCHEMBL22585908 0.73 DHODH (0.44) GAAGRM4MAPK1
SCHEMBL31441507 0.73 ROCK2 (0.40) LRRK2ROCK2PDE10A
SCHEMBL18865627 0.73 OPRL1 (0.38) ROCK2
SCHEMBL29691063 0.73 OPRL1 (0.38) ROCK2
SCHEMBL18342440 0.72 MEN1 (0.38) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270222-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-08-28 — — US disclosed
US-20250122207-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-04-17 — — US disclosed
WO-2025054448-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122207-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF AAK1, CAMKK1, AP2A1 LRRK2 485/4885KDM4E 3245/4885GAA 878/4885
US-20250270222-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF AAK1, AP2A1, CSNK1A1 LRRK2 499/4885KDM4E 2966/4885GAA 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback